Human BioSystems
OTC Bulletin Board : HBSC

Human BioSystems

July 18, 2005 07:00 ET

Human BioSystems Successfully Transplants Kidneys Stored at Suspended Animation Temperatures

PALO ALTO, CALIFORNIA--(CCNMatthews - July 18, 2005) - Human Biosystems (OTCBB:HBSC) announces today that it was successful in transplanting animal kidneys preserved in the Company's proprietary "HBS Preservation Solution" after being stored in liquid Nitrogen at -196 degrees Centigrade.

Dr. Luis Toledo, Chief Medical Officer for HBS states, "We believe that this is the first time that an organ stored at such a low temperature was then thawed and transplanted back into the animals while still maintaining some of its functional response as evidenced by the presence of urine. In this series of experiments, three rat kidneys, containing the 'HBS Preservation Solution', were stored at -196 degrees Centigrade for 3, 5 and 7 days respectively, then returned to room temperature prior to transplantation back into the animal. All three kidneys produced urine after transplantation, the most important indication of organ viability. All kidneys tested in these experiments had a Reperfusion Index of 14 out of a possible15 (the RPI is one indicator of an organs viability), which is excellent."

Dr. Toledo added, "This extremely low temperature causes all metabolic activity to virtually cease. An organ stored at this temperature remains in a state of suspended animation known as vitrification. In order to achieve the successful vitrification of an organ, many obstacles must be overcome; including the effects that freezing has on the organ. The damage caused by the crystallization and expansion of water in an unprotected organ is catastrophic, causing cells to be completely destroyed."

"HBS Preservation Solution limited expansion to about one tenth to that of normal water expansion and caused the water to freeze in a different way, thus avoiding the normal organ damage resulting from water freezing," stated Dr. Fernando Lopez, Senior Research Scientist for HBS.

"This latest milestone represents the potential for our technology to become an enabling technology for not only organ preservation uses, but for applications we never imagined possible," states Harry Masuda, CEO of HBS.

HBS is headquartered in Palo Alto, California with research facilities in Michigan.

Certain statements contained herein are ``forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, results from ongoing research and development as well as clinical studies, failure to obtain regulatory approval for the Company's products, if required, failure to develop a product based on the Company's technology, failure of any such products to compete effectively with existing products, the ability of the Company to fund marketing and sales efforts that may be required to effectively sell its products .and other factors discussed in filings made by the Company with the Securities and Exchange Commission.

Contact Information